Search

Background: The adults ITP is often insidious & reveals diversity in the clinical course. These individuals usually seek medical help for muco-cutanaeous or subcutaneous bleeds, while the clinical picture can range from asymptomatic to life-threatening. Aim: To determine the frequency of common clinical and laboratory attributes in newly diagnosed immune thrombocytopenic purpura. Study Design: Descriptive cross sectional. Methodology: Present study was conducted at Pathology Department, Jinnah Hospital Lahore. A total of 95 patients with newly diagnosed immune thrombocytopenic purpura, age 20-50 years of both gender were included. Patients history of anticoagulant drugs or steroid use for last 1 month, CLD, CRF and post- radiotherapy or chemotherapy were excluded. After this, common clinical and laboratory attributes (hemorrhagic manifestations, hemoglobin levels, platelet count) in newly diagnosed immune thrombocytopenic purpura were noted. Data was analyzed using SPSS version 20. The chi-square tests was used to compare the groups. A p-value of 0.05 was considered significant. Results: Hemorrhagic manifestations in newly diagnosed immune thrombocytopenic purpura was found in 41 (43.16%) patients. The mean hemoglobin & platelets counts at presentation was 10.35 ± 1.43g/d l& 45.47 ± 2.07 x 109/l. Conclusion: It was concluded that hemorrhagic manifestations in newly diagnosed immune1thrombocytopenic purpura were found in about half of the patients. Keywords: Immune1Thrombocytopenic Purpura, Immunoglobulin and Platelet Count.

Background: Chronic myeloid leukemia (CML) is a clonal myelo-proliferative disorder of a pluripotent stem cell. Aim: To find the frequency of low, intermediate and high risk category in patients of chronic myeloid leukemia and to compare frequency of complete molecular response. Study design: Descriptive case series. Methodology: Present study was conducted at Hematology Department, Sheikh Zayed Hospital Lahore. 260 patients fulfilled the selection criteria were selected. Sokal score was calculated. Low risk, intermediate and high risk category was assessed. Patients were followed up for 3 months. BCR-ABL translocation detection was done after 3months of treatment and complete molecular response was recorded. All this information was recorded on proforma. Data was analyzed using SPSS version 20. The chi-square test was used to compare the groups. A p-value of 0.05 was considered significant. Results: The mean age of patients was 49.18±20.33years. There were 144(55.4%) males and 116(44.6%) females. The mean duration of CML diagnosis was 3.52±1.69months. At baseline, 172 (66.2%) had low risk, 76(29.2%) had intermediate risk and 12 (4.6%) had high risk. In the study, complete molecular response was observed in 0% patients. Conclusion: It was concluded that there is regression in grades of Sokal score in patients of Chronic myeloid leukemia after 3 months treatment with TKIs but there is no complete molecular response observed in any patient after 3 months of treatment with TKIs. Keywords: Chronic Myeloid Leukemia, Low, Intermediate, High Risk and Sokal Score.